MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Introduction Wound debridement is a critical medical procedure used to treat various types of wounds, including burns, <a target=_blank href= ...

The addition of Marion General means the Lifeline of Ohio Placenta Donation Program will be available at all OhioHealth ...

A key driver is the rising prevalence of chronic wounds. The global wound care devices market is projected to hit $4b by 2032 ...

Wound Care Devices Market Growth is Fueled by Rising Chronic Wound Prevalence and Technological InnovationsPune, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Wound Care Devices Market Size & Growth Analysis: ...

Detailed price information for Celularity Inc WT (CELUW-Q) from The Globe and Mail including charting and trades.

diabetic foot ulcers, and venous leg ulcers use skin substitutes as part of their treatment. These substitutes temporarily or permanently replace the skin’s structure and function, promoting ...

a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.